Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2016-06 Issue:6 Volume:4 Page:445-453
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Behr Jürgen,Bendstrup Elisabeth,Crestani Bruno,Günther Andreas,Olschewski Horst,Sköld C Magnus,Wells Athol,Wuyts Wim,Koschel Dirk,Kreuter Michael,Wallaert Benoît,Lin Chin-Yu,Beck Jürgen,Albera Carlo

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference19 articles.

1. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011

2. Classification and natural history of the idiopathic interstitial pneumonias;Kim;Proc Am Thorac Soc,2006

3. Clinical course and prediction of survival in idiopathic pulmonary fibrosis;Ley;Am J Respir Crit Care Med,2011

4. Idiopathic pulmonary fibrosis;Meltzer;Orphanet J Rare Dis,2008

5. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia;Strand;Chest,2014

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF);Expert Review of Clinical Pharmacology;2024-08-27

2. Evidence from recent clinical trials in fibrotic interstitial lung diseases;Current Opinion in Pulmonary Medicine;2024-07-04

3. Cutaneous Photosensitivity Diseases;Rook's Textbook of Dermatology;2024-03-19

4. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency;American Journal of Respiratory and Critical Care Medicine;2024-03-15

5. Disruption of extracellular redox balance drives persistent lung fibrosis and impairs fibrosis resolution;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2023-12